Pembrolizumab prolongs PFS vs. chemotherapy for certain patients with colorectal cancer

Pembrolizumab monotherapy demonstrated superior PFS and PFS2 compared with standard-of-care chemotherapy among patients with microsatellite-instability high/mismatch repair-deficient metastatic colorectal cancer.Pembrolizumab (Keytruda, Merck), an anti-PD-1 antibody, also had an acceptable safety profile, with fewer treatment-associated adverse events than chemotherapy, according to results of the phase KEYNOTE-177 trial presented at Gastrointestinal Cancers Symposium.“We know that microsatellite instability is detected in only around 5% of patients with advanced colon cancer,”Read More

Share on facebook
Share on twitter
Share on linkedin